newsfilter
← Latest News
GlobeNewswire·

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built